Mergers & Acquisitions ·
Innate Pharma SA announced that its strategic partnership with Sobi is now effective following the expiration of…
IPHAInnate Pharma SA
Innate Pharma SA announced that its strategic partnership with Sobi is now effective following the expiration of antitrust waiting periods and completion of other conditions. The closing triggers a USD 75 million upfront payment to Innate Pharma. This event marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study for lacutamab in cutaneous T-cell lymphoma, with the first patient expected in Q1 2027. Under the agreement, Sobi holds exclusive global commercialization rights upon potential accelerated approval and may assume full development rights following positive Phase 3 results. Innate Pharma is a clinical-stage biotechnology company developing immunotherapies for cancer patients.